Value2022202320242025TTMSelling/general/admin expenses29.82 M43.39 M50.16 M52.35 M56.47 MResearch & development86.72 M147.91 M155.29 M160.64 M154.18 MOperating income-116.54 M-204.79 M-202.47 M-208.35 M-206.61 MNon-Operating Income, Total-6.22 M6.38 M6.58 M7.21 M8.24 MInterest expense, net of interest capitalized—————Non-Operating Income, excl. Interest Expenses-8.13 M-2.38 M6.54 M7.06 M8.08 MUnusual income/expense1.9 M8.76 M41 K148 K162 KPretax income-122.77 M-198.41 M-195.88 M-201.14 M-198.37 MEquity in earnings—————Taxes-948 K-279 K00—Non-controlling/minority interest—————After tax other income/expense0————Net income before discontinued operations-121.82 M-198.13 M-195.88 M-201.14 M-198.37 MDiscontinued operations—————Net income-121.82 M-198.13 M-195.88 M-201.14 M-198.37 MDilution adjustment00———Preferred dividends20.19 M0———Diluted net income available to common stockholders-142.01 M-198.13 M-195.88 M-201.14 M-198.37 MBasic earnings per share (Basic EPS)-4.19-2.18-1.65-1.35-1.23Diluted earnings per share (Diluted EPS)-4.19-2.18-1.65-1.35-1.23Average basic shares outstanding33.89 M90.97 M118.6 M148.76 M—Diluted shares outstanding33.89 M90.97 M118.6 M148.76 M—EBITDA-114.32 M-199.97 M-196.34 M-201.03 M—EBIT-116.54 M-204.62 M-202.47 M-208.35 M—Cost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)2.22 M4.65 M6.13 M7.32 M7.48 M
Prime Medicine, Inc. - Common Stock
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.